Avalyn
formerly Avalyn PharmaceuticalsIPOAvalyn Pharma Inc | Targeted therapies for rare lung diseases
Boston, United States · Founded 2011 · $434.5M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2011
- Business Model
- B2B
- Website
- avalynpharma.com
- Total Funding
- $434.5M
- Last Round
- $100.0M Series DJul 2025
- Rounds
- 6
About
Avalyn is a clinical-stage biopharmaceutical company developing inhaled formulations of approved medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. By delivering drugs directly to the lungs via inhalation, Avalyn aims to improve efficacy and reduce systemic side effects compared to existing oral treatments. The company is led by CEO Lyn Baranowski and CSO Mark Surber, PhD.
Summary
Avalyn is a Biotech company based in Boston, United States, founded in 2011. It has raised $434.5M in total across 6 rounds, most recently a $100.0M Series D round in Jul 2025. Investors include SR One, Novo Holdings A/S and Shiv Chaudhary.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Apr 2026
Sign up to see all 7 rounds
Seed through IPO — per-round amounts, valuations, and who invested in each round.
Investors
SR One
2 rounds
Novo Holdings A/S
2 rounds
Shiv Chaudhary
2 rounds
Eight Roads Ventures
2 rounds
Suvretta Capital Management
1 round
Eventide Asset Management
1 round
Perceptive Advisors
1 round
Catalio Capital Management
1 round
F-Prime Capital
1 round
Pivotal bioVenture Partners
1 round
RiverVest Venture
1 round
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/avalyn"><img src="https://indexed.vc/api/badge/company/avalyn" alt="Avalyn on Indexed.vc" width="260" height="76" /></a>